Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.28 -0.22 (-1.26%)

Delayed Quote Updated: 1:14 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

36 37 Next >

Can Solid Biosciences Challenge Sarepta in the DMD Market?

April 08, 2025

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

Via MarketBeat

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead

April 08, 2025

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to...

Via StockStory

Topics Supply Chain

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

April 07, 2025

From Pomerantz LLP

Via GlobeNewswire

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗

April 07, 2025

Via The Motley Fool

Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops ↗

April 04, 2025

H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.

Via Stocktwits

Topics Government

Sarepta Therapeutics Provides Update on ELEVIDYS

April 04, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death ↗

April 03, 2025

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Via Benzinga

Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday ↗

April 03, 2025

Via Benzinga

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death ↗

April 03, 2025

The holds are temporary while the teenager's death is under investigation.

Via Investor's Business Daily

Topics Death

Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings) ↗

April 03, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

April 03, 2025

From Pomerantz LLP

Via GlobeNewswire

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

April 03, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...

Via StockStory

Topics Artificial Intelligence

This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

April 02, 2025

Via Benzinga

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving

March 31, 2025

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price...

Via StockStory

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Is This Stock a Buy After a Massive 20% Drop in 1 Day? ↗

March 23, 2025

Via The Motley Fool

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up ↗

March 21, 2025

Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.

Via Stocktwits

Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

March 18, 2025

U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31

Via Benzinga

Topics Economy Stocks

12 Analysts Have This To Say About Sarepta Therapeutics ↗

March 18, 2025

Via Benzinga

Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday? ↗

March 18, 2025

Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York.

Via Benzinga

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge ↗

March 18, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 18, 2025

Via Benzinga

Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today

March 18, 2025

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with...

Via StockStory

Discover the top movers in Tuesday's pre-market session. ↗

March 18, 2025

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges ↗

March 18, 2025

Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor.

Via Benzinga

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.